Clinical Trial Update: Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of dalantercept in combination with axitinib for advanced renal cell carcinoma was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• dalantercept (dalantercept)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Advanced Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2021-05-24